Theophylline Anhydrous

Theophylline Anhydrous

SCHEMBL5037

Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Theophylline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A known ✓ P27815 9/20 0.81
PDE4B known ✓ Q07343 9/20 0.81
PDE4C known ✓ Q08493 9/20 0.81
PDE4D known ✓ Q08499 9/20 0.81
ADORA2A known ✓ P29274 8/20 0.81
ADORA2B known ✓ P29275 8/20 0.81
ADORA3 known ✓ P0DMS8 4/20 0.81
ADORA1 known ✓ P30542 2/20 0.81
PDE3B known ✓ Q13370 1/20 0.58
PDE3A known ✓ Q14432 1/20 0.58
CYP1A2 P05177 2/20 1.00
LMNA P02545 1/20 1.00
MAPT P10636 1/20 1.00
ATAD2 Q6PL18 1/20 0.84
PIK3CD O00329 1/20 0.81
ALPL P05186 1/20 0.81
TMIGD3 P0DMS9 1/20 0.81
CYP2C19 P33261 1/20 0.81
HIF1A Q16665 1/20 0.81
CFTR P13569 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Theophylline Anhydrous SCHEMBL393183 1.00 CYP1A2 (1.00) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL1321168 1.00 CYP1A2 (1.00) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL5181434 1.00 CYP1A2 (1.00) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL1022085 0.98 CYP1A2 (0.97) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL9792548 0.98 CYP1A2 (0.97) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL19987964 0.98 CYP1A2 (0.97) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL7546366 0.98 CYP1A2 (0.97) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL11187438 0.98 CYP1A2 (0.97) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL8719730 0.97 CYP1A2 (0.94) CYP1A2LMNAMAPTATAD2PDE4A
Theophylline Anhydrous SCHEMBL28274666 0.95 CYP1A2 (0.91) CYP1A2LMNAMAPTATAD2PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 32944 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120789080-B Therapeutic drug for chronic obstructive pulmonary disease THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY (CN) 2026-05-26 CN claimed
US-12616651-B2 Topical lipolysis composition and methods Lipodissolve Therapeutics Inc. (CA) 2026-05-05 US claimed
US-12576085-B2 Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer SAWYER MICHAEL BRUCE (CA) 2026-03-17 US claimed
US-20260069551-A1 Patch for treating demyelinating diseases UNIV MAINZ JOHANNES GUTENBERG (DE) 2026-03-12 US claimed
US-20260060914-A1 CONTOUR INJECTION COMPOSITION HONG JONG CHEOL (KR) 2026-03-05 US claimed
US-12550694-B2 Selective deposition for integrated circuit interconnect structures TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2026-02-10 US claimed
EP-4679085-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP claimed
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES INC (US) 2025-11-27 US claimed
US-20250352565-A1 Compositions for Improving Physiological Function with Age THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-11-20 US claimed
US-12472186-B2 Pharmaceutical compositions and methods of treating cardiovascular diseases Cardix Therapeutics LLC (US) 2025-11-18 US claimed
EP-0046289-A2 Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates MERCK & CO. INC. (US) 1982-02-24 EP claimed
EP-0046291-A2 Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates MERCK & CO. INC. (US) 1982-02-24 EP claimed
US-4235236-A Device for dispensing drug by combined diffusional and osmotic operations ALZA CORPORATION (US) 1980-11-25 US claimed
US-4235870-A COMPRISING A HIGHER ALIPHATIC ALCOHOL AND A HYDRATED HYDROXYALKYL CELLULOSE SYNGERGISTICS (US) 1980-11-25 US claimed
EP-0015684-A1 Zinc aminophylline, its preparation and pharmaceutical use Research Corporation (US) 1980-09-17 EP claimed
US-4187286-A POLYETHYLENE GLYCOL, SPERMICIDE, THICKENER, EFFERVESCENT AGENT, ALGINIC ACID G&W Laboratories, Inc. (US) 1980-02-05 US claimed
US-4073907-A CARBON DIOXIDE-FREE, SODIUM EDETATE, CRYSTAL GROWTH INHIBITION ABBOTT LABORATORIES (US) 1978-02-14 US claimed
US-4014334-A Laminated osmotic system for dispensing beneficial agent ALZA CORPORATION (US) 1977-03-29 US claimed
US-4008719-A Osmotic system having laminar arrangement for programming delivery of active agent ALZA CORPORATION (US) 1977-02-22 US claimed
US-3965256-A ALCOHOL AND HYDRATED HYDROXYALKYL CELLULOSE SYNERGISTICS (US) 1976-06-22 US claimed